BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 1st Quarter - Report

ACT FOR ULTRA RARE

via AVIVA STRATEGIES (FKA MGB CONSULTING)

1st Quarter (Jan 1 - Mar 31) · 2026Posted Apr 20, 2026Filing document ↗LDA record ↗

Income$38Kfee reported

Client

Name: ACT FOR ULTRA RARE
Description: Advocacy for ultra rare disease
Location: District of Columbia · United States of America

Registrant

Firm: AVIVA STRATEGIES (FKA MGB CONSULTING)
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Ultra rare disease advocacy
Lobbyistsmr MAX GABRIEL BRONSTEIN
TargetedHOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

ACT FOR ULTRA RARE — Lobbying — Receipts Report